Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study

Background: Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. Objective: In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients trea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Allergy and asthma proceedings 2025-01, Vol.46 (1), p.45-51
Hauptverfasser: Papaioannou, Andriana I., Kallieri, Maria, Zervas, Eleftherios, Fouka, Evangelia, Porpodis, Konstantinos, Hadji Mitrova, Marija, Tzortzaki, Eleni, Makris, Michael, Ntakoula, Maria, Lyberopoulos, Panagiotis, Dimakou, Katerina, Koukidou, Sofia, Ampelioti, Sevasti, Papaporfyriou, Anastasia, Katsoulis, Konstantinos, Kipourou, Maria, Rovina, Nikoletta, Antoniou, Katerina, Vittorakis, Stylianos, Bakakos, Petros, Steiropoulos, Paschalis, Markopoulou, Katerina, Avarlis, Panteleimon, Papanikolaou, Ιlias C., Markatos, Miltiadis, Gaki, Eleni, Samitas, Konstantinos, Glynos, Konstantinos, Papiris, Spyros A., Papakosta, Despoina, Tzanakis, Nikolaos, Gaga, Mina, Kostikas, Konstantinos, Loukides, Stelios
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 51
container_issue 1
container_start_page 45
container_title Allergy and asthma proceedings
container_volume 46
creator Papaioannou, Andriana I.
Kallieri, Maria
Zervas, Eleftherios
Fouka, Evangelia
Porpodis, Konstantinos
Hadji Mitrova, Marija
Tzortzaki, Eleni
Makris, Michael
Ntakoula, Maria
Lyberopoulos, Panagiotis
Dimakou, Katerina
Koukidou, Sofia
Ampelioti, Sevasti
Papaporfyriou, Anastasia
Katsoulis, Konstantinos
Kipourou, Maria
Rovina, Nikoletta
Antoniou, Katerina
Vittorakis, Stylianos
Bakakos, Petros
Steiropoulos, Paschalis
Markopoulou, Katerina
Avarlis, Panteleimon
Papanikolaou, Ιlias C.
Markatos, Miltiadis
Gaki, Eleni
Samitas, Konstantinos
Glynos, Konstantinos
Papiris, Spyros A.
Papakosta, Despoina
Tzanakis, Nikolaos
Gaga, Mina
Kostikas, Konstantinos
Loukides, Stelios
description Background: Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. Objective: In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Methods: Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function. Results: A total of 146 patients were evaluated; remission was achieved in 40 (27.4%) and 29 (22%) after 12 and 24 months, respectively. At 12 months, the patients in remission had a better baseline ACT score (17.0 [14.0-19.0] versus 15.0 [12.0-17.0]; p = 0.027), were more rarely using OCS (35% versus 62.2%; p = 0.004), and required a lower baseline dose of OCS (5.0 mg/day [5.0-10.0 mg/day] versus 10.0 mg/day [5.0-15.0 mg/day]; p = 0.042) at baseline, whereas, at 24 months, they less frequently carried a baseline diagnosis of gastroesophageal reflux disease (GERD) (10.3% versus 32%; p = 0.031) and used lower doses of OCS at baseline (5.0 [1.0-5.0] versus 10.0 [5.0-15.0]; p = ≤0.001) versus nonremitters; 52.5% of patients had sustained remission, whereas 42.5% experienced relapse. These patients more frequently had GERD versus patients with sustained remission (52.9% versus 4.8%; p = 0.002). Finally, regression analysis has shown that GERD was the only predictor of relapse. Conclusion: Remitters had better asthma control and needed lower doses or no maintenance OCS at baseline, whereas GERD seems to be an important factor that affects remission and relapse.Clinical trial NCT04084613, www.clinical trials.gov
doi_str_mv 10.2500/aap.2025.46.240084
format Article
fullrecord <record><control><sourceid>proquest_ingen</sourceid><recordid>TN_cdi_proquest_miscellaneous_3150523059</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>ocean/aap/2025/00000046/00000001/art00011</ingid><sourcerecordid>3150523059</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2580-bfd0c8c9dfe553f364419eeb80340efe70638258ceb8f1fda4631f119cc61b8c3</originalsourceid><addsrcrecordid>eNp1kkGL1DAUx4so7rr6BTxIwIuXji9N2mm9DcOqCwOK6Dmk6ctMljapSbrLLPjdTaejC4K5vBB-7_dI_smy1xRWRQnwXspxVUBRrni1KjhAzZ9kl7RkTV4x4E_THuo6LzktLrIXIdwCUM6q6nl2wZo1p2wNl9mvbW-sUbInHgcTgnGWGEtGGQ3aGMi9iQcS8A49EnTBWDceTG8UkSEeBkmiRxmxW7gBR9ebh2mQ7QeyIaMLMT-4xFrZH4MJxGny7Xp3sz9EEuLUHV9mz7TsA74616vsx8fr79vP-e7Lp5vtZperoqwhb3UHqlZNp7EsmWYV57RBbGtgHFDjGipWJ1KlI011J3nFqKa0Uaqiba3YVfZu8Y7e_ZwwRJHuqrDvpUU3BcFoCWXBoGwS-vYf9NZNPl3gRKXBUFBIVLFQyrsQPGoxejNIfxQUxByOSOGIORzBK7GEk5renNVTO2D3t-VPGgnYLICx-_T68nG0UyjtoxNOK5mXDVAhfZwrTY6v_3EYddbM32L-FeKOV5aejECTAzgD0aGWUx9FlF7sH0RIyt9mZLsu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3154410210</pqid></control><display><type>article</type><title>Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Papaioannou, Andriana I. ; Kallieri, Maria ; Zervas, Eleftherios ; Fouka, Evangelia ; Porpodis, Konstantinos ; Hadji Mitrova, Marija ; Tzortzaki, Eleni ; Makris, Michael ; Ntakoula, Maria ; Lyberopoulos, Panagiotis ; Dimakou, Katerina ; Koukidou, Sofia ; Ampelioti, Sevasti ; Papaporfyriou, Anastasia ; Katsoulis, Konstantinos ; Kipourou, Maria ; Rovina, Nikoletta ; Antoniou, Katerina ; Vittorakis, Stylianos ; Bakakos, Petros ; Steiropoulos, Paschalis ; Markopoulou, Katerina ; Avarlis, Panteleimon ; Papanikolaou, Ιlias C. ; Markatos, Miltiadis ; Gaki, Eleni ; Samitas, Konstantinos ; Glynos, Konstantinos ; Papiris, Spyros A. ; Papakosta, Despoina ; Tzanakis, Nikolaos ; Gaga, Mina ; Kostikas, Konstantinos ; Loukides, Stelios</creator><creatorcontrib>Papaioannou, Andriana I. ; Kallieri, Maria ; Zervas, Eleftherios ; Fouka, Evangelia ; Porpodis, Konstantinos ; Hadji Mitrova, Marija ; Tzortzaki, Eleni ; Makris, Michael ; Ntakoula, Maria ; Lyberopoulos, Panagiotis ; Dimakou, Katerina ; Koukidou, Sofia ; Ampelioti, Sevasti ; Papaporfyriou, Anastasia ; Katsoulis, Konstantinos ; Kipourou, Maria ; Rovina, Nikoletta ; Antoniou, Katerina ; Vittorakis, Stylianos ; Bakakos, Petros ; Steiropoulos, Paschalis ; Markopoulou, Katerina ; Avarlis, Panteleimon ; Papanikolaou, Ιlias C. ; Markatos, Miltiadis ; Gaki, Eleni ; Samitas, Konstantinos ; Glynos, Konstantinos ; Papiris, Spyros A. ; Papakosta, Despoina ; Tzanakis, Nikolaos ; Gaga, Mina ; Kostikas, Konstantinos ; Loukides, Stelios</creatorcontrib><description>Background: Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. Objective: In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Methods: Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function. Results: A total of 146 patients were evaluated; remission was achieved in 40 (27.4%) and 29 (22%) after 12 and 24 months, respectively. At 12 months, the patients in remission had a better baseline ACT score (17.0 [14.0-19.0] versus 15.0 [12.0-17.0]; p = 0.027), were more rarely using OCS (35% versus 62.2%; p = 0.004), and required a lower baseline dose of OCS (5.0 mg/day [5.0-10.0 mg/day] versus 10.0 mg/day [5.0-15.0 mg/day]; p = 0.042) at baseline, whereas, at 24 months, they less frequently carried a baseline diagnosis of gastroesophageal reflux disease (GERD) (10.3% versus 32%; p = 0.031) and used lower doses of OCS at baseline (5.0 [1.0-5.0] versus 10.0 [5.0-15.0]; p = ≤0.001) versus nonremitters; 52.5% of patients had sustained remission, whereas 42.5% experienced relapse. These patients more frequently had GERD versus patients with sustained remission (52.9% versus 4.8%; p = 0.002). Finally, regression analysis has shown that GERD was the only predictor of relapse. Conclusion: Remitters had better asthma control and needed lower doses or no maintenance OCS at baseline, whereas GERD seems to be an important factor that affects remission and relapse.Clinical trial NCT04084613, &lt;ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinical trials.gov"&gt;www.clinical trials.gov&lt;/ext-link&gt;</description><identifier>ISSN: 1088-5412</identifier><identifier>ISSN: 1539-6304</identifier><identifier>EISSN: 1539-6304</identifier><identifier>DOI: 10.2500/aap.2025.46.240084</identifier><identifier>PMID: 39741370</identifier><language>eng</language><publisher>United States: OceanSide Publications, Inc</publisher><subject>Adult ; Aged ; Anti-Asthmatic Agents - therapeutic use ; Antibodies, Monoclonal, Humanized - administration &amp; dosage ; Antibodies, Monoclonal, Humanized - therapeutic use ; Asthma ; Asthma - diagnosis ; Asthma - drug therapy ; Biological effects ; Clinical trials ; Corticoids ; Corticosteroids ; Female ; Gastroesophageal reflux ; Humans ; Key Words: Clinical Remission ; Leukocytes (eosinophilic) ; Male ; Mepolizumab ; Middle Aged ; Monoclonal antibodies ; Predictors Of Remission And Relapse ; Real World ; Regression analysis ; Relapse ; Relight Study ; Remission ; Remission (Medicine) ; Remission Induction ; Respiratory function ; Responders ; Severe Eosinophilic Asthma ; Severity of Illness Index ; Super-Responders ; Sustained Remission ; Treatment Outcome</subject><ispartof>Allergy and asthma proceedings, 2025-01, Vol.46 (1), p.45-51</ispartof><rights>Copyright OceanSide Publications 2025</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2580-bfd0c8c9dfe553f364419eeb80340efe70638258ceb8f1fda4631f119cc61b8c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39741370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Papaioannou, Andriana I.</creatorcontrib><creatorcontrib>Kallieri, Maria</creatorcontrib><creatorcontrib>Zervas, Eleftherios</creatorcontrib><creatorcontrib>Fouka, Evangelia</creatorcontrib><creatorcontrib>Porpodis, Konstantinos</creatorcontrib><creatorcontrib>Hadji Mitrova, Marija</creatorcontrib><creatorcontrib>Tzortzaki, Eleni</creatorcontrib><creatorcontrib>Makris, Michael</creatorcontrib><creatorcontrib>Ntakoula, Maria</creatorcontrib><creatorcontrib>Lyberopoulos, Panagiotis</creatorcontrib><creatorcontrib>Dimakou, Katerina</creatorcontrib><creatorcontrib>Koukidou, Sofia</creatorcontrib><creatorcontrib>Ampelioti, Sevasti</creatorcontrib><creatorcontrib>Papaporfyriou, Anastasia</creatorcontrib><creatorcontrib>Katsoulis, Konstantinos</creatorcontrib><creatorcontrib>Kipourou, Maria</creatorcontrib><creatorcontrib>Rovina, Nikoletta</creatorcontrib><creatorcontrib>Antoniou, Katerina</creatorcontrib><creatorcontrib>Vittorakis, Stylianos</creatorcontrib><creatorcontrib>Bakakos, Petros</creatorcontrib><creatorcontrib>Steiropoulos, Paschalis</creatorcontrib><creatorcontrib>Markopoulou, Katerina</creatorcontrib><creatorcontrib>Avarlis, Panteleimon</creatorcontrib><creatorcontrib>Papanikolaou, Ιlias C.</creatorcontrib><creatorcontrib>Markatos, Miltiadis</creatorcontrib><creatorcontrib>Gaki, Eleni</creatorcontrib><creatorcontrib>Samitas, Konstantinos</creatorcontrib><creatorcontrib>Glynos, Konstantinos</creatorcontrib><creatorcontrib>Papiris, Spyros A.</creatorcontrib><creatorcontrib>Papakosta, Despoina</creatorcontrib><creatorcontrib>Tzanakis, Nikolaos</creatorcontrib><creatorcontrib>Gaga, Mina</creatorcontrib><creatorcontrib>Kostikas, Konstantinos</creatorcontrib><creatorcontrib>Loukides, Stelios</creatorcontrib><title>Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study</title><title>Allergy and asthma proceedings</title><addtitle>Allergy Asthma Proc</addtitle><description>Background: Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. Objective: In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Methods: Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function. Results: A total of 146 patients were evaluated; remission was achieved in 40 (27.4%) and 29 (22%) after 12 and 24 months, respectively. At 12 months, the patients in remission had a better baseline ACT score (17.0 [14.0-19.0] versus 15.0 [12.0-17.0]; p = 0.027), were more rarely using OCS (35% versus 62.2%; p = 0.004), and required a lower baseline dose of OCS (5.0 mg/day [5.0-10.0 mg/day] versus 10.0 mg/day [5.0-15.0 mg/day]; p = 0.042) at baseline, whereas, at 24 months, they less frequently carried a baseline diagnosis of gastroesophageal reflux disease (GERD) (10.3% versus 32%; p = 0.031) and used lower doses of OCS at baseline (5.0 [1.0-5.0] versus 10.0 [5.0-15.0]; p = ≤0.001) versus nonremitters; 52.5% of patients had sustained remission, whereas 42.5% experienced relapse. These patients more frequently had GERD versus patients with sustained remission (52.9% versus 4.8%; p = 0.002). Finally, regression analysis has shown that GERD was the only predictor of relapse. Conclusion: Remitters had better asthma control and needed lower doses or no maintenance OCS at baseline, whereas GERD seems to be an important factor that affects remission and relapse.Clinical trial NCT04084613, &lt;ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinical trials.gov"&gt;www.clinical trials.gov&lt;/ext-link&gt;</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - administration &amp; dosage</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - diagnosis</subject><subject>Asthma - drug therapy</subject><subject>Biological effects</subject><subject>Clinical trials</subject><subject>Corticoids</subject><subject>Corticosteroids</subject><subject>Female</subject><subject>Gastroesophageal reflux</subject><subject>Humans</subject><subject>Key Words: Clinical Remission</subject><subject>Leukocytes (eosinophilic)</subject><subject>Male</subject><subject>Mepolizumab</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Predictors Of Remission And Relapse</subject><subject>Real World</subject><subject>Regression analysis</subject><subject>Relapse</subject><subject>Relight Study</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Remission Induction</subject><subject>Respiratory function</subject><subject>Responders</subject><subject>Severe Eosinophilic Asthma</subject><subject>Severity of Illness Index</subject><subject>Super-Responders</subject><subject>Sustained Remission</subject><subject>Treatment Outcome</subject><issn>1088-5412</issn><issn>1539-6304</issn><issn>1539-6304</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kkGL1DAUx4so7rr6BTxIwIuXji9N2mm9DcOqCwOK6Dmk6ctMljapSbrLLPjdTaejC4K5vBB-7_dI_smy1xRWRQnwXspxVUBRrni1KjhAzZ9kl7RkTV4x4E_THuo6LzktLrIXIdwCUM6q6nl2wZo1p2wNl9mvbW-sUbInHgcTgnGWGEtGGQ3aGMi9iQcS8A49EnTBWDceTG8UkSEeBkmiRxmxW7gBR9ebh2mQ7QeyIaMLMT-4xFrZH4MJxGny7Xp3sz9EEuLUHV9mz7TsA74616vsx8fr79vP-e7Lp5vtZperoqwhb3UHqlZNp7EsmWYV57RBbGtgHFDjGipWJ1KlI011J3nFqKa0Uaqiba3YVfZu8Y7e_ZwwRJHuqrDvpUU3BcFoCWXBoGwS-vYf9NZNPl3gRKXBUFBIVLFQyrsQPGoxejNIfxQUxByOSOGIORzBK7GEk5renNVTO2D3t-VPGgnYLICx-_T68nG0UyjtoxNOK5mXDVAhfZwrTY6v_3EYddbM32L-FeKOV5aejECTAzgD0aGWUx9FlF7sH0RIyt9mZLsu</recordid><startdate>20250101</startdate><enddate>20250101</enddate><creator>Papaioannou, Andriana I.</creator><creator>Kallieri, Maria</creator><creator>Zervas, Eleftherios</creator><creator>Fouka, Evangelia</creator><creator>Porpodis, Konstantinos</creator><creator>Hadji Mitrova, Marija</creator><creator>Tzortzaki, Eleni</creator><creator>Makris, Michael</creator><creator>Ntakoula, Maria</creator><creator>Lyberopoulos, Panagiotis</creator><creator>Dimakou, Katerina</creator><creator>Koukidou, Sofia</creator><creator>Ampelioti, Sevasti</creator><creator>Papaporfyriou, Anastasia</creator><creator>Katsoulis, Konstantinos</creator><creator>Kipourou, Maria</creator><creator>Rovina, Nikoletta</creator><creator>Antoniou, Katerina</creator><creator>Vittorakis, Stylianos</creator><creator>Bakakos, Petros</creator><creator>Steiropoulos, Paschalis</creator><creator>Markopoulou, Katerina</creator><creator>Avarlis, Panteleimon</creator><creator>Papanikolaou, Ιlias C.</creator><creator>Markatos, Miltiadis</creator><creator>Gaki, Eleni</creator><creator>Samitas, Konstantinos</creator><creator>Glynos, Konstantinos</creator><creator>Papiris, Spyros A.</creator><creator>Papakosta, Despoina</creator><creator>Tzanakis, Nikolaos</creator><creator>Gaga, Mina</creator><creator>Kostikas, Konstantinos</creator><creator>Loukides, Stelios</creator><general>OceanSide Publications, Inc</general><general>OceanSide Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20250101</creationdate><title>Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study</title><author>Papaioannou, Andriana I. ; Kallieri, Maria ; Zervas, Eleftherios ; Fouka, Evangelia ; Porpodis, Konstantinos ; Hadji Mitrova, Marija ; Tzortzaki, Eleni ; Makris, Michael ; Ntakoula, Maria ; Lyberopoulos, Panagiotis ; Dimakou, Katerina ; Koukidou, Sofia ; Ampelioti, Sevasti ; Papaporfyriou, Anastasia ; Katsoulis, Konstantinos ; Kipourou, Maria ; Rovina, Nikoletta ; Antoniou, Katerina ; Vittorakis, Stylianos ; Bakakos, Petros ; Steiropoulos, Paschalis ; Markopoulou, Katerina ; Avarlis, Panteleimon ; Papanikolaou, Ιlias C. ; Markatos, Miltiadis ; Gaki, Eleni ; Samitas, Konstantinos ; Glynos, Konstantinos ; Papiris, Spyros A. ; Papakosta, Despoina ; Tzanakis, Nikolaos ; Gaga, Mina ; Kostikas, Konstantinos ; Loukides, Stelios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2580-bfd0c8c9dfe553f364419eeb80340efe70638258ceb8f1fda4631f119cc61b8c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - administration &amp; dosage</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - diagnosis</topic><topic>Asthma - drug therapy</topic><topic>Biological effects</topic><topic>Clinical trials</topic><topic>Corticoids</topic><topic>Corticosteroids</topic><topic>Female</topic><topic>Gastroesophageal reflux</topic><topic>Humans</topic><topic>Key Words: Clinical Remission</topic><topic>Leukocytes (eosinophilic)</topic><topic>Male</topic><topic>Mepolizumab</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Predictors Of Remission And Relapse</topic><topic>Real World</topic><topic>Regression analysis</topic><topic>Relapse</topic><topic>Relight Study</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Remission Induction</topic><topic>Respiratory function</topic><topic>Responders</topic><topic>Severe Eosinophilic Asthma</topic><topic>Severity of Illness Index</topic><topic>Super-Responders</topic><topic>Sustained Remission</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papaioannou, Andriana I.</creatorcontrib><creatorcontrib>Kallieri, Maria</creatorcontrib><creatorcontrib>Zervas, Eleftherios</creatorcontrib><creatorcontrib>Fouka, Evangelia</creatorcontrib><creatorcontrib>Porpodis, Konstantinos</creatorcontrib><creatorcontrib>Hadji Mitrova, Marija</creatorcontrib><creatorcontrib>Tzortzaki, Eleni</creatorcontrib><creatorcontrib>Makris, Michael</creatorcontrib><creatorcontrib>Ntakoula, Maria</creatorcontrib><creatorcontrib>Lyberopoulos, Panagiotis</creatorcontrib><creatorcontrib>Dimakou, Katerina</creatorcontrib><creatorcontrib>Koukidou, Sofia</creatorcontrib><creatorcontrib>Ampelioti, Sevasti</creatorcontrib><creatorcontrib>Papaporfyriou, Anastasia</creatorcontrib><creatorcontrib>Katsoulis, Konstantinos</creatorcontrib><creatorcontrib>Kipourou, Maria</creatorcontrib><creatorcontrib>Rovina, Nikoletta</creatorcontrib><creatorcontrib>Antoniou, Katerina</creatorcontrib><creatorcontrib>Vittorakis, Stylianos</creatorcontrib><creatorcontrib>Bakakos, Petros</creatorcontrib><creatorcontrib>Steiropoulos, Paschalis</creatorcontrib><creatorcontrib>Markopoulou, Katerina</creatorcontrib><creatorcontrib>Avarlis, Panteleimon</creatorcontrib><creatorcontrib>Papanikolaou, Ιlias C.</creatorcontrib><creatorcontrib>Markatos, Miltiadis</creatorcontrib><creatorcontrib>Gaki, Eleni</creatorcontrib><creatorcontrib>Samitas, Konstantinos</creatorcontrib><creatorcontrib>Glynos, Konstantinos</creatorcontrib><creatorcontrib>Papiris, Spyros A.</creatorcontrib><creatorcontrib>Papakosta, Despoina</creatorcontrib><creatorcontrib>Tzanakis, Nikolaos</creatorcontrib><creatorcontrib>Gaga, Mina</creatorcontrib><creatorcontrib>Kostikas, Konstantinos</creatorcontrib><creatorcontrib>Loukides, Stelios</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Allergy and asthma proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papaioannou, Andriana I.</au><au>Kallieri, Maria</au><au>Zervas, Eleftherios</au><au>Fouka, Evangelia</au><au>Porpodis, Konstantinos</au><au>Hadji Mitrova, Marija</au><au>Tzortzaki, Eleni</au><au>Makris, Michael</au><au>Ntakoula, Maria</au><au>Lyberopoulos, Panagiotis</au><au>Dimakou, Katerina</au><au>Koukidou, Sofia</au><au>Ampelioti, Sevasti</au><au>Papaporfyriou, Anastasia</au><au>Katsoulis, Konstantinos</au><au>Kipourou, Maria</au><au>Rovina, Nikoletta</au><au>Antoniou, Katerina</au><au>Vittorakis, Stylianos</au><au>Bakakos, Petros</au><au>Steiropoulos, Paschalis</au><au>Markopoulou, Katerina</au><au>Avarlis, Panteleimon</au><au>Papanikolaou, Ιlias C.</au><au>Markatos, Miltiadis</au><au>Gaki, Eleni</au><au>Samitas, Konstantinos</au><au>Glynos, Konstantinos</au><au>Papiris, Spyros A.</au><au>Papakosta, Despoina</au><au>Tzanakis, Nikolaos</au><au>Gaga, Mina</au><au>Kostikas, Konstantinos</au><au>Loukides, Stelios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study</atitle><jtitle>Allergy and asthma proceedings</jtitle><addtitle>Allergy Asthma Proc</addtitle><date>2025-01-01</date><risdate>2025</risdate><volume>46</volume><issue>1</issue><spage>45</spage><epage>51</epage><pages>45-51</pages><issn>1088-5412</issn><issn>1539-6304</issn><eissn>1539-6304</eissn><abstract>Background: Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. Objective: In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Methods: Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function. Results: A total of 146 patients were evaluated; remission was achieved in 40 (27.4%) and 29 (22%) after 12 and 24 months, respectively. At 12 months, the patients in remission had a better baseline ACT score (17.0 [14.0-19.0] versus 15.0 [12.0-17.0]; p = 0.027), were more rarely using OCS (35% versus 62.2%; p = 0.004), and required a lower baseline dose of OCS (5.0 mg/day [5.0-10.0 mg/day] versus 10.0 mg/day [5.0-15.0 mg/day]; p = 0.042) at baseline, whereas, at 24 months, they less frequently carried a baseline diagnosis of gastroesophageal reflux disease (GERD) (10.3% versus 32%; p = 0.031) and used lower doses of OCS at baseline (5.0 [1.0-5.0] versus 10.0 [5.0-15.0]; p = ≤0.001) versus nonremitters; 52.5% of patients had sustained remission, whereas 42.5% experienced relapse. These patients more frequently had GERD versus patients with sustained remission (52.9% versus 4.8%; p = 0.002). Finally, regression analysis has shown that GERD was the only predictor of relapse. Conclusion: Remitters had better asthma control and needed lower doses or no maintenance OCS at baseline, whereas GERD seems to be an important factor that affects remission and relapse.Clinical trial NCT04084613, &lt;ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinical trials.gov"&gt;www.clinical trials.gov&lt;/ext-link&gt;</abstract><cop>United States</cop><pub>OceanSide Publications, Inc</pub><pmid>39741370</pmid><doi>10.2500/aap.2025.46.240084</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1088-5412
ispartof Allergy and asthma proceedings, 2025-01, Vol.46 (1), p.45-51
issn 1088-5412
1539-6304
1539-6304
language eng
recordid cdi_proquest_miscellaneous_3150523059
source MEDLINE; Alma/SFX Local Collection
subjects Adult
Aged
Anti-Asthmatic Agents - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - therapeutic use
Asthma
Asthma - diagnosis
Asthma - drug therapy
Biological effects
Clinical trials
Corticoids
Corticosteroids
Female
Gastroesophageal reflux
Humans
Key Words: Clinical Remission
Leukocytes (eosinophilic)
Male
Mepolizumab
Middle Aged
Monoclonal antibodies
Predictors Of Remission And Relapse
Real World
Regression analysis
Relapse
Relight Study
Remission
Remission (Medicine)
Remission Induction
Respiratory function
Responders
Severe Eosinophilic Asthma
Severity of Illness Index
Super-Responders
Sustained Remission
Treatment Outcome
title Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A08%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_ingen&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20remission%20in%20patients%20with%20severe%20eosinophilic%20asthma%20treated%20with%20mepolizumab:%20A%20post-hoc%20analysis%20of%20RELIght%20study&rft.jtitle=Allergy%20and%20asthma%20proceedings&rft.au=Papaioannou,%20Andriana%20I.&rft.date=2025-01-01&rft.volume=46&rft.issue=1&rft.spage=45&rft.epage=51&rft.pages=45-51&rft.issn=1088-5412&rft.eissn=1539-6304&rft_id=info:doi/10.2500/aap.2025.46.240084&rft_dat=%3Cproquest_ingen%3E3150523059%3C/proquest_ingen%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3154410210&rft_id=info:pmid/39741370&rft_ingid=ocean/aap/2025/00000046/00000001/art00011&rfr_iscdi=true